Document is current
Any future updates will be listed below
-
Authors
Yang, Yeon-Suk
Kim, Jung-Min https://orcid.org/0000-0002-9072-4293
Xie, Jun https://orcid.org/0000-0001-9565-1567
Chaugule, Sachin https://orcid.org/0000-0001-6323-2034
Lin, Chujiao
Ma, Hong
Hsiao, Edward https://orcid.org/0000-0001-8924-106X
Hong, Jaehyoung
Chun, Hyonho
Shore, Eileen M. https://orcid.org/0000-0003-2609-6971
Kaplan, Frederick S.
Gao, Guangping https://orcid.org/0000-0003-0097-9012
Shim, Jae-Hyuck https://orcid.org/0000-0002-4947-3293
-
Funding
Funding for this research was provided by:
International Fibrodysplasia Ossificans Progressiva Association
- License Information
-
More Information
Article History
Received: 11 May 2022
Accepted: 4 October 2022
First Online: 19 October 2022
Competing interests
: G.G. and J.-H.S. have submitted a patent application concerning the methodology described in this study. G.G. and J.-H.S. are scientific co-founders of AAVAA Therapeutics and hold equity in this company. G.G. is also a scientific co-founder of Voyager Therapeutics and Aspa Therapeutics and holds equity in these companies. G.G. is an inventor on patents with potential royalties licensed to Voyager Therapeutics, Aspa Therapeutics Inc., and other biopharmaceutical companies. E.C.H. serves in a volunteer capacity on the registry advisory board of the IFOPA; on the International Clinical Council on FOP, and on the Fibrous Dysplasia Foundation Medical Advisory Board. E.C.H. received prior research support through his institution from Regeneron Pharmaceuticals. E.C.H. receives clinical trials research support through his institution from Clementia, an Ipsen company. F.S.K. is the founder and past-President of the International Clinical Council (ICC) on FOP. F.S.K. serves in a volunteer capacity on the registry advisory board of the IFOPA. F.S.K. is an investigator on clinical trials sponsored by Clementia, an Ipsen company, and by Regeneron Pharmaceuticals. E.M.S. serves in a volunteer capacity as a research advisor to the IFOPA. These pose no competing interests for this study. Other authors declare no competing interests.
